261 related articles for article (PubMed ID: 31656583)
1. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
F1000Res; 2019; 8():. PubMed ID: 31656583
[TBL] [Abstract][Full Text] [Related]
2. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
[TBL] [Abstract][Full Text] [Related]
4. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
[TBL] [Abstract][Full Text] [Related]
5. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
Akinci G; Akinci B
Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
[TBL] [Abstract][Full Text] [Related]
6. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?
Machado MV; Cortez-Pinto H
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):513-5. PubMed ID: 23985000
[TBL] [Abstract][Full Text] [Related]
7. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
[TBL] [Abstract][Full Text] [Related]
8. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
[TBL] [Abstract][Full Text] [Related]
9. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
[TBL] [Abstract][Full Text] [Related]
10. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
[TBL] [Abstract][Full Text] [Related]
11. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
[TBL] [Abstract][Full Text] [Related]
12. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
13. Treatment Options for Lipodystrophy in Children.
Mainieri F; Tagi VM; Chiarelli F
Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
[TBL] [Abstract][Full Text] [Related]
14. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.
Polyzos SA; Perakakis N; Mantzoros CS
Metabolism; 2019 Jul; 96():66-82. PubMed ID: 31071311
[TBL] [Abstract][Full Text] [Related]
15. [Lipodystrophy. Mechanisms, clinical presentation, therapy].
Miehle K; Stumvoll M; Fasshauer M
Internist (Berl); 2011 Apr; 52(4):362, 364-6, 368-70 passim. PubMed ID: 21424143
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
Nagayama A; Ashida K; Watanabe M; Moritaka K; Sonezaki A; Kitajima Y; Takahashi H; Yoshinobu S; Iwata S; Yasuda J; Hasuzawa N; Ozono S; Motomura S; Nomura M
Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Cellular Bases of Lipodystrophy Syndromes.
Zammouri J; Vatier C; Capel E; Auclair M; Storey-London C; Bismuth E; Mosbah H; Donadille B; Janmaat S; Fève B; Jéru I; Vigouroux C
Front Endocrinol (Lausanne); 2021; 12():803189. PubMed ID: 35046902
[TBL] [Abstract][Full Text] [Related]
18. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
Lebastchi J; Ajluni N; Neidert A; Oral EA
J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101
[TBL] [Abstract][Full Text] [Related]
19. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
Tchang BG; Shukla AP; Aronne LJ
Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
[TBL] [Abstract][Full Text] [Related]
20. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
